news and events

press releases

publications

• corporate publications
• scientific publications
• conference publications

videos

To accomplish our mission we need people who enjoy working in a dynamic...
 
 



Press releases  

23/12/2009 - Novexel to be acquired by AstraZeneca

Paris, France, December 23, 2009 -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing. The transaction is expected to close in the first quarter of 2010, subject to certain customary conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.  

Download PDF - 30 ko

06/11/2009 - Novexel Starts Phase II Clinical Trial with NXL103 in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Paris, France, November 6, 2009 -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid (Zyvox, Pfizer NYSE:PFE).  

Download PDF - 29 ko

11/09/2009 - Novexel presents 16 posters and one slide presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in San Francisco

Paris, France, 11 September 2009 – Novexel, a specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of 16 posters and one slide presentation at the 49th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The ICAAC meeting, which is taking place in San Francisco, California, September 12-15 2009, is the leading global conference on anti-microbial agents globally with over 10,000 participants.   

Download PDF - 85 ko

18/05/2009 - Novexel to present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its two most advanced pipeline products NXL104 and NXL103 are the subject of four posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The ECCMID conference is taking place in Helsinki between 16th and 19th May 2009.  

Download PDF - 73 ko

26/03/2009 - Novexel Strengthens its Scientific Advisory Board with the Appointment of Dr. Karen Bush

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today the appointment of Dr. Karen Bush to the Company’s Scientific Advisory Board (SAB). Novexel’s SAB is chaired by Dr. David Shlaes who sits on the Company’s board. Dr. Bush, who is currently Adjunct Professor at the Department of Biology at Indiana University, brings extensive experience and knowledge of the anti-infectives field to Novexel’s SAB.  

Download PDF - 27 ko

03/03/2009 - Novexel’s NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients with complicated Intra-Abdominal Infections (cIAIs)

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines Novexel’s broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered a second Phase II clinical trial.  

Download PDF - 29 ko

12/11/2008 - Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients with complicated Urinary Tract Infections

Novexel announces today that its most advanced injectable antibacterial, which combines Novexel's broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered Phase II clinical trials.   

Download PDF - 29 ko

24/10/2008 - Novexel Appoints Dr. Kenneth Coleman as Chief Scientific Officer

Novexel announced today that it has appointed Dr. Kenneth Coleman as its Chief Scientific Officer (CSO). Dr. Coleman joined Novexel on 1st October, 2008.   

Download PDF - 26 ko

Print this page

> Stachyra, T., Levasseur, P., Péchereau, M-C., Girard, A-M., Claudon, M., Miossec C., Black M.T. In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases, Journal of Antimicrobial Chemotherapy (2009) 64 (2), 326-329.


> See all publications